2025 Diabetes Update

UNMC Dr. Stanley M. and Dorothy Truhlsen Campus Events Center
(located on the first floor of the Michael F. Sorrell Center for Health Science Education)
619 S 42nd Street, Omaha, NE 68105

Parking: 

Complimentary parking for campus visitors is available in Lots 61, 62, and 63 off of 40th Street between Leavenworth and Mason Streets. Download the parking map.

A designated shuttle will be available for symposium participants. Look for the glass enclosure on the north-west corner of lot 63. The shuttle will run on a continuous loop from 6:30–8:30 a.m. and again at the end of the symposium.

If you are an employee/student of UNMC/Nebraska Medicine, please park in your regularly assigned parking area. UNMC CCE is not responsible for any parking citation a participant may incur while attending this symposium.

• You will need to install Zoom on your desktop, tablet, or smartphone.
• Check your email for instructions on how to join the live stream.

The 2025 Diabetes Update convenes leading clinicians and researchers as they present the latest advancements in diabetes care.

This symposium will focus on emerging technologies, novel pharmacotherapies, nutritional interventions, and evidence-based obesity management.

Through case-based discussions—including rapid insulin titration and the role of gut hormones in metabolic regulation—you’ll gain practical insights to enhance your clinical decision-making.

You’ll also explore strategies for interpreting diabetes technology data, applying pattern management, and optimizing treatment approaches in complex cases.

Designed for diabetes care professionals, this symposium provides essential knowledge and skills to improve patient outcomes in everyday practice.

At the conclusion of this activity, participants should be better able to:

1. Analyze and interpret data from diabetes-related technologies.
2. Implement pattern management strategies in diabetes care.
3. Identify pharmacologic agents used in the treatment of diabetes.  
4. Describe the impact of nutrition on diabetes management.

In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Nebraska Medicine. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
The University of Nebraska Medical Center designates this live activity for a maximum of 7.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
7.00 Contact Hours Awarded
Nebraska Medicine is approved as a provider of nursing continuing professional development by VTL Center for Professional Development, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. Approval #: NE1025-2

Pharmacists
The University of Nebraska Medical Center designates this activity for 7.00 ACPE contact hours. Pharmacists should claim only the credit commensurate with the extent of their participation in the activity. Credit will be provided to NABP CPE Monitor within 30 days after the activity completion.

Dietitians and Licensed Medical Nutrition Therapists
The 2025 Diabetes Update Symposium awards 7.00 Continuing Professional Education Units (CPEUs) in accordance with the Commission on Dietetic Registration’s CPEU Prior Approval Program.

Read the UNMC CCE Disclosure Declaration Policy

Disclosures

The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles.

FACULTY

The following have disclosed relevant financial relationships:

• Dan Bessesen, MD
  Research: Lilly USA, LLC; Novo Nordisk A/S; Pfizer Inc.
  INVESTIGATIONAL/OFF-LABEL USE OF DRUGS DISCLOSURES
  Discussion of phentermine for long-term obesity management; Discussion of bupropion, naltrexone, and topiramate for stand-alone obesity treatment
• Sarah Keegan, MS, RDN, LMNT, CDCES
  Contracted Certified Pump Trainer: Tandem Diabetes Care, Inc.
• Miranda Kuhr, PharmD, BCACP
  INVESTIGATIONAL/OFF-LABEL USE OF DRUGS DISCLOSURES
  Drug discussion reviewing 2-3 medications in phase 3 trials that are not FDA approved
• Emily Pietrantone, APRN-NP
  INVESTIGATIONAL/OFF-LABEL USE OF DRUGS DISCLOSURES
  Discussion of open-source automated insulin delivery systems
• Caressa Trueman, PharmD, BCACP, BC-ADM*
  INVESTIGATIONAL/OFF-LABEL USE OF DRUGS DISCLOSURES
  Drug discussion reviewing 2-3 medications in phase 3 trials that are not FDA approved

The following have nothing to disclose:

• Hythem Abouodah, MD
• Felipe Naranjo, MD
• Jill Wagoner, MD*
• David Waters, DPM, FACFAS

PLANNING COMMITTEE

The following have nothing to disclose:

• Cece Abbey-Webben, MS
• Holly Dubas
• Kelsey Hathorn, MSN, RN
• Lori Huebert, BSN, RN
• Katie Jochum, MHA
• Shelly Kelley, BSN, RN, CDCES
• Jodi Kennedy
• Melissa Lockard, BSN, RN, CDCES
• Mitzi Infante Magana, PA-C
• Brenda Ram, CMP, CHCP
• Jackie Siebels, BSN, RN, NPD-BC
• Holly Vail, RD, LMNT, CDCES
• Shannan Wilson, RRT

*Planning committee and faculty member